Objective: Numerous studies have been trying to disentangle the complex pathophysiology of autism spectrum disorders (ASD). In our study, we explored the potential role of maternal serum (MS) alpha-fetoprotein (AFP) in the prediction and the pathophysiology of ASD.
A member of albuminlike family proteins, AFP has been used for many years as a tumour marker in oncology and an indicator (or sign) of fetal defects in antenatal care. 1 This large glycoprotein is synthesized by the fetal liver and the yolk sac during pregnancy. It crosses the placenta through a receptor-mediated mechanism to eventually reach the maternal circulation, where it peaks around week 32 of gestation followed by decreasing levels until delivery. [2] [3] [4] Abnormally high or lower levels of AFP are often considered indicative of a fetal defect or pregnancy complications. While levels of MS-AFP are abnormally increased in numerous complications, such as NTDs, pre-eclampsia, and fetal death; low levels of MS-AFP are seen in Down's syndrome pregnancies during the second trimester of pregnancy. 3 Besides the strong evidence supporting the use of MS-AFP as a screening marker, recent studies have pointed toward a potential role of AFP as an antioxidant and a cell growth modulator through apoptosis, signal transduction, and cytostatic or cytotoxic mechanisms. 5 Further, it has been postulated that AFP may play a role in the suppression of a mother's immune response to the developing embryo, the same way as in a patient with a developing tumour. 6 Interestingly, these potential roles fit well into theories explaining the pathophysiology of autism, where oxidative stress 7 and immunologic dysfunction components have been investigated in numerous studies. 8 To our knowledge, no studies have investigated the relation between MS-AFP levels and autism. To test the hypothesis that MS-AFP levels are abnormally different in people later to be diagnosed with autism, compared with control subjects, we conducted a case-control study using MS-AFP as an exposure.
Methods
Patients and control subjects were retrieved from an HBC established and maintained at SSI in Copenhagen. The HBC includes amniotic fluid and MS samples of about 100 000 pregnant women from 1980 to 2004. 9 ASD cases in the HBC were identified through the DPCR, using a unique identifier assigned to every citizen in Denmark (the CPR number) and based on the ICD-8, Danish Revision, codes 299.xx 10 to 1993 and ICD-10 codes DF84.xx 11 from 1994 to 2000. In the ICD classification, the definition of infantile autism has changed from psychosis proto-infantalis in ICD-8 (code 299.00) to childhood autism in ICD-10 (code F84.0). However, the other ASD diagnoses were included in more specific diagnostic entities in ICD-10. The transition from ICD-8 to ICD-10 has considerably improved the definition of the diagnostic entities of ASD. 12 We also used the DPCR data supplemented by data from the DNHR to control for psychiatric comorbidities and congenital malformation diagnoses in our study population. DPCR and DNHR data are computerized and have been collected systematically from all psychiatric wards and hospitals in Denmark since 1969 and 1977, respectively. 13, 14 Diagnoses of ADHD ICD-10 codes (DF90.xx), depression ICD-8 codes (296.xx) and ICD-10 codes (DF30.xx-34.xx, 38.xx, and 39.xx), and schizophrenia ICD-8 codes (295.xx) and ICD-10 codes (DF 20.xx-21.xx) were dichotomously recoded into 3 different variables (ADHD, depression, and schizophrenia). However, for congenital malformation diagnoses, ICD-8 codes (740.xx-759.xx) and ICD-10 codes (DQ00.xx-DQ99.xx) were used. The data regarding the subjects' obstetric history were retrieved from the Danish Medical Birth Registry. This registry has been computerized since 1973 and includes data on all live births, stillbirths, and infant deaths in Denmark. 15 The MS-AFP measurements were retrieved from a large MS-AFP screening program introduced in 3 well-defined areas of Denmark. 16 This multicentre screening program was initiated in 1980 and offered MS-AFP screening for all pregnant women attending antenatal clinics at any centre included in the program. 17 The AFP assays were carried out by the same laboratory during the entire study period, 18 and the database comprising all of the patients participating in the program was created and maintained at SSI. This includes each participant's CPR number, date of MS-AFP sampling, gestational week of sampling, sample identification number, and MS-AFP level recorded in both The International System of Units (kIU/L) and standardized units as MoMs. MoMs were calculated by dividing the absolute value of MS-AFP by the median level of MS-AFP for all live singleton births in the screening program, controlling for both gestational week and calendar year. To explore the pattern of MS-AFP in patients and control subjects, we used 2.5 MoM as a cut-off value, as it is the most commonly reported cut-off value for abnormal MS-AFP levels. 19 Further, the 10th and 90th percentiles of MS-AFP concentration were calculated based on our control population, and MS-AFP levels were dichotomized based In our main analysis, we included all live-born singleton people in the HBC with at least one ASD diagnosis and a corresponding MS-AFP measurement in the MS-AFP database after excluding siblings. However, the control subjects were non-ASD offsprings identified from the HBC using the same inclusion criteria.
A supplementary analysis was conducted comparing ASD patients to 2 subsets of control subjects included in our study. The 2 subsets were control subjects who had at least 1 childhood psychiatric disorder other than ASD, and control subjects who did not have any psychiatric comorbidity. This made it feasible to compare ASD (specifically, infantile autism) patients to control subjects with nonpsychiatric comorbidities and with other childhood psychiatric disorders. 
Statistical Analysis
We analyzed the data using logistic regression models and nonparametric tests; the associations between dichotomized MS-AFP level and ASD or other childhood psychiatric disorder were described using odds ratios and 95% confidence intervals. We calculated both crude and adjusted odds ratios. In the adjusted analysis, we controlled for sex, year of birth, any previous diagnosis of congenital disorder or fetal birth defect, other psychiatric comorbidities, and pre-eclampsia. We also controlled for previously identified risk factors of ASD: maternal and paternal age, birth weight, gestational age, Apgar score, and parity. 20, 21 In addition, when analyzing MS-AFP concentrations at the 10th and 90th percentile cut-off values, we adjusted for sampling week of gestation to control for changing MS-AFP levels during pregnancy.
We also analyzed MS-AFP concentration on a continuous scale. As different transformation methods did not yield a normal distribution of MS-AFP measurements, we opted for nonparametric tests. To examine the differences in the overall distribution of MS-AFP in patients and control subjects, we used the Wilcoxon Mann-Whitney U test. However, for our supplementary analyses, we used the Kruskal-Wallis test to examine the difference between ASD patients and the 2 control groups simultaneously.
IBM PASW statistics 18.0 22 was used for data management and the statistical analyses were performed using Stata statistical software, version 11.0.
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Results
A total of 112 ASD patients and 243 control subjects met our inclusion criteria. Our ASD patient population included 22 with infantile autism, 40 with Asperger syndrome, and 50 subjects diagnosed with other ASD diagnoses. Study participants' year of birth ranged from 1982 to 1996 and had the same distribution both for patients and for control subjects. The mean age of ASD diagnosis (defined by the first date of admission registered in the DPCR) was 11.6 years (interquartile range 9.1 to 14.9). MS samples were obtained mostly in the second trimester, and only 12 subjects (3 patients and 9 control subjects) had first-trimester MS samples (9 to 12 gestational weeks). Figure 1 shows the concentrations of MS-AFP (kIU/L) expressed as medians over gestational weeks. Concentrations, both of ASD patients and of control subjects, were increasing over gestational weeks, and no distinct pattern can be indentified in patients, compared with control subjects (Figure 1 ).
When exploring MS-AFP measurements using different cut-off values, our crude regression model estimates showed statistically significant differences for the MS-AFP measurement falling above 2.5 MoM in ASD patients, compared with the control subjects (OR 2.33; 95% CI 1.00 to 5.39, P = 0.05), but not for 10th and 90th percentile cut-off values. MS-AFP levels were still significant after excluding subjects with congenital malformation diagnoses (OR 2.60; 95% CI 1.04 to 6.51, P = 0.04). Excluding subjects with other psychiatric comorbidities still yields estimates in the same direction but lacked statistical significance (OR 2.47; 95% CI 0.59 to 10.29, P = 0.22).
In our adjusted estimates, differences between ASD patients and control subjects were not statistically significant for any of the 3 cut-off values used. However, the effect was still in the same direction, and, with the exception of excluding subjects with other psychiatric comorbidities, the estimates were slightly stronger. Table 2 lists the crude and the adjusted odds ratios with the 95% confidence intervals for 
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ASD patients, compared with the control subjects. Further, stratification by sex or by having a congenital malformation diagnosis revealed no statistically significant difference (P values of test of homogeneity were 0.76 and 0.57 for sex and congenital malformation, respectively).
On a continuous scale, we found no significant difference in the overall distribution of MS-AFP in the ASD patients, compared with the control subjects; mean MS-AFP value was 45.54 kIU/L with an interquartile range of 25.00 to 53.5 for patients, and 41.24 kIU/L with an interquartile range of 25.00 to 47.00 for control subjects (Wilcoxon MannWhitney U test: z = -1.04, P = 0.30).
In a supplementary analysis, levels of MS-AFP in infantile autism patients were compared with those of control subjects with no psychiatric disorders, other childhood psychiatric disorder were compared with control subjects with no psychiatric disorders, and finally infantile autism patients were compared with those with other childhood psychiatric disorder. As seen in Table 3 , infantile autism patients tend to have MS-AFP above 2.5 MoM more than other childhood psychiatric disorder, albeit statistically insignificant. Further, our analyses did not show a statistically significant difference when analyzing these 3 groups (infantile autism, other childhood psychiatric disorder, and control subjects with no psychiatric disorders) together on a continuous scale with a Kruskal-Wallis test P value of 0.40.
Discussion
Our findings cautiously suggest a different pattern of MS-AFP in ASD patients, compared with control subjects or other childhood psychiatric disorders. ASD patients tend to have MS-AFP levels significantly above 2.5 MoM; more than control subjects regardless of congenital malformation co-diagnoses. In addition, our study confirmed the previous findings of the potential role of advanced paternal age in the development of ASD and the significant association between being diagnosed with a congenital malformation disorder and ASD. 8 While our study targeted a special Danish population, that is, mothers who participated in a multicentre MS-AFP screening program and had entry in our autism HBC, the universality of the screening program within each centre in the study (screening was offered to all women who were pregnant in each county) and the advantage of obtaining all of our covariates independently of the exposure helped to minimize the potential effects of biases related to differential misclassification and selection.
While Denmark enjoys demographic stability, a unique citizen identifier, and almost universal access to health services, 14, 24 our study still has the typical limitations of register-based studies. All psychiatric and somatic diagnoses were retrieved from nationwide registers, and we had no information on symptomatology to validate the diagnoses. Moreover, 2 different diagnostic tools were used (ICD-8 and ICD-10). In general, the registries are maintained and validated regularly by the National Board of Health. 24 The majority of patients (97.3%) were diagnosed using ICD-10, and only 3 were diagnosed based on ICD-8. Excluding patients diagnosed with ICD-8 did not change our estimates. Also, specifically for diagnoses in the DPCR, a recent validation study of ASD diagnoses based on expert review has confirmed infantile autism diagnoses in 94% of the patients analyzed. 25 Besides the well documented classical role of MS-AFP in screening for NTDs, 26 there is growing evidence suggesting a potential beneficial role of MS-AFP in the prediction of other disorders, such as preterm birth 27 and adverse maternal or fetal outcomes in general. 28 Previous population-based studies have also documented the association between MS-AFP and cryptorchidism 29 and maternal breast cancer during pregnancy, 30 yet the literature is limited about the role of AFP in ASD.
It is plausible from a biologic point of view, as well as from an epidemiologic perspective, that MS-AFP may play a role (directly or indirectly) in the prediction and the pathophysiology of ASD. From a pathophysiology perspective, AFP fits well within numerous important potential pathways for developing autism. Immunologic disturbance, 31 brain lateralization, 32 and oxidative stress theories 33 are 3 main (not necessarily mutual exclusive) theories proposed for developing ASD. The ability of AFP to induce dysfunction and apoptosis of antigen-presenting cells, 34 the high affinity of AFP to bind to estrogens and its effects on defeminization and masculization traits in animal studies, 35 and finally, the documented physiochemical role of AFP as an antioxidant, 5 all together support a potential role of AFP in the development of ASD. Further, the documented association between MS-AFP and adverse maternal or fetal outcomes, 28 which also have been linked to ASD as potential risk factors, 8 necessitates further research in this area.
Finally, it is important to emphasize that our study is exploratory. Unfortunately, we lacked statistical power owing to a relatively small sample size. In general, the effect measures did increase in the adjusted model (although they were statistically insignificant), which could indicate a true effect that is hidden by our lack of statistical power. The power was 50% at a P value of less than 0.05 to detect an odds ratio of 2.6. With our sample size, 80% power would require an odds ratio of not less than 3.3. Although the lack of statistical power limits, to some extent, the generalizability of our conclusions, having MS-AFP measurements as part of routine antenatal care in several countries creates many opportunities for further larger-scale studies to examine the potential role of MS-AFP in ASD.
In conclusion, this exploratory study suggests a different pattern of MS-AFP in ASD patients, compared with control subjects. Biologic plausibility of its role in the pathophysiology of ASD makes AFP a good candidate for further larger-scale studies to confirm such an association and to determine whether this pattern is unique to ASD or related to other psychiatric disorders. The analysis of MS-AFP is feasible and cost-effective because it is part of routine antenatal screening for NTDs in several countries.
Résumé : Les troubles du spectre de l'autisme et les niveaux d'alpha-foetoprotéine sérique maternelle durant la grossesse Objectif : De nombreuses études ont tenté de démêler la pathophysiologie complexe des troubles du spectre de l'autisme (TSA). Dans notre étude, nous avons exploré le rôle potentiel de l'alpha-foetoprotéine (AFP) sérique maternelle (SM) dans la prédiction de la pathophysiologie des TSA.
Méthodes : Un total de 112 patients souffrant de TSA et de 243 sujets témoins ont été inclus dans une étude cas-témoin, à l'aide des cohortes de naissance par génération tenues par le Statens Serum Institute. Les mesures d'AFP-SM ont été obtenues d'un programme de dépistage multicentrique, tandis que les données cliniques provenaient de registres nationaux. L'association entre l'AFP-SM et le statut de TSA a été analysée à l'aide de modèles de régression logistique et de tests non paramétriques.
Résultats : Les estimations brutes, mais non corrigées, montraient que les niveaux d'AFP-SM étaient légèrement, mais non significativement, plus élevés chez les mères d'enfants souffrant des TSA, comparativement à leurs homologues témoins. Les personnes souffrant de TSA avaient un rapport de cotes de 2,33, avec des intervalles de confiance à 95 % de 1,00 à 5,39, pour avoir un taux d'AFP-SM supérieur à 2,5 multiples de la médiane. L'exclusion de sujets ayant des comorbidités de malformations congénitales n'a pas modifié la direction de nos estimations (RC 2,60; IC à 95 % 1,04 à 6,51; P = 0,04).
Conclusion :
La plausibilité biologique du rôle de l'AFP dans la pathophysiologie des TSA en fait un bon candidat pour d'autres études à plus grande échelle, afin de confirmer cette association et de déterminer si ce modèle est unique aux TSA ou s'il est lié à d'autres troubles psychiatriques également.
